Headlines about Soligenix (NASDAQ:SNGX) have been trending positive on Friday, Accern Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Soligenix earned a daily sentiment score of 0.31 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.6263155077293 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Soligenix (NASDAQ SNGX) traded down $0.04 during mid-day trading on Friday, reaching $2.13. The company’s stock had a trading volume of 35,926 shares, compared to its average volume of 88,192. The company has a market cap of $18.95, a PE ratio of -2.11 and a beta of 2.17. Soligenix has a 52-week low of $1.74 and a 52-week high of $5.08.
Soligenix (NASDAQ:SNGX) last released its earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.32) by $0.15. The firm had revenue of $1.82 million during the quarter, compared to analysts’ expectations of $1.36 million. Soligenix had a negative return on equity of 112.81% and a negative net margin of 90.93%. research analysts anticipate that Soligenix will post -1.2 earnings per share for the current year.
SNGX has been the subject of a number of research reports. Maxim Group set a $5.00 target price on Soligenix and gave the stock a “buy” rating in a report on Wednesday, January 3rd. HC Wainwright reiterated a “buy” rating and set a $5.50 target price (down previously from $11.00) on shares of Soligenix in a report on Monday, November 6th.
In other news, insider Spa Essetifin bought 293,510 shares of the stock in a transaction on Wednesday, November 29th. The stock was purchased at an average price of $2.12 per share, for a total transaction of $622,241.20. The transaction was disclosed in a filing with the SEC, which is available at this link. 5.03% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “Soligenix (SNGX) Earning Favorable Press Coverage, Report Finds” was posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.truebluetribune.com/2018/01/19/soligenix-sngx-earning-favorable-press-coverage-report-finds.html.
Soligenix, Inc is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.